PRESS RELEASE 21st March 2019
Mogrify to host careers open day at Bio-Innovation Centre, Cambridge Science Park
- The event will take place on Friday, 16th August 2019 from 4–6pm, at Mogrify offices, 25 Cambridge Science Park
- Opportunity to find out about careers in the biotech industry, tour the research laboratories and meet the founders and current employees at Mogrify
- Mogrify is recruiting up to 30 commercial, operational and scientific roles
Cambridge, UK, 17 July 2019: Mogrify Ltd (Mogrify®), a company aiming to transform the future development of cell therapies, today announced it will host a careers day at the Bio-Innovation Centre, 25 Cambridge Science Park on Friday, 16th August 2019 from 4–6pm. The event will showcase careers in the biotech industry, specifically in cell therapy and regenerative medicine, and offer attendees the opportunity to visit the Company’s research laboratories, and meet with the founders and current employees.
Mogrify has developed a proprietary direct cellular conversion technology, which makes it possible to transform any mature cell type into any other, bypassing the pluripotent stem cell- or progenitor cell-state. Mogrify’s platform simultaneously addresses the challenges associated with efficacy, safety and scalability in the development and manufacture of lifesaving cell therapies.
Mogrify’s CEO, Dr. Darrin M. Disley, OBE, a renowned scientist, entrepreneur, angel investor and enterprise champion who has started, grown or invested in over 40 start-up life science, technology and social enterprises will provide the opening remarks and introduction at the careers open day. Mogrify’s scientific co-founders; CSO, Professor Julian Gough, a bioinformatician and biotech entrepreneur; CTO, Assistant Professor Owen Rackham, a leading academic in the application of machine learning and complex systems in cell reprograming; and CMO, Professor Jose Polo who has worked at the cuttingedge of cell reprograming for over a decade, will also give short presentations.
Dr. Darrin M. Disley, OBE, CEO, Mogrify, said: “Mogrify offers an exciting opportunity to work at the forefront of cell reprograming. We have up to 30 commercial, operational and scientific research roles available and look forward to welcoming those looking for a career in the biotech industry to our new facilities at the Bio-Innovation Centre, Cambridge Science Park.”
For further information about the event and free registration, please visit: Careers
Notes to Editors
Mogrify leadership team
For high-resolution and alternate images please contact Zyme Communications.
For further information please contact:
Darrin M Disley, PhD, OBE
Tel: +44 (0)7811 996 942
About Mogrify www.mogrify.co.uk
Mogrify has developed a proprietary direct cellular conversion technology, which makes it possible to transform (transmogrify) any mature human cell type into any other without going through a pluripotent stem cell- or progenitor cell-state.
The platform takes a systematic big-data approach to identify, from next-generation sequencing and
gene-regulatory networks, the transcription factors (in vitro) or small molecules (in vivo), needed to convert a cell. By bypassing the stem cell-stage of cell transformation, Mogrify simultaneously addresses challenges associated with efficacy, safety and scalability.
Mogrify is applying its patented technology to generate IP and cell types that will power the development and manufacture of new cell therapies across every therapeutic area.
Uniquely positioned to address a cell therapy market estimated to be $35 billion USD by 2023, Mogrify is commercializing its technology via IP licensing, product development, and drug development. Based in Cambridge, UK, the Company has raised $3.7 million USD seed funding from Ahren Innovation Capital, 24Haymarket and Dr Darrin M Disley, OBE.
About Darrin M Disley, PhD, DSc, OBE
Darrin is a scientist, entrepreneur, angel investor and enterprise champion who has raised $500 million USD business financing and closed $600 million USD in commercial deals.
For 11 years he was CEO of Horizon Discovery Group plc a company he led from seed funding to a $113 million USD IPO and a peak market capitalization of $550 million USD.
In recent years, he has been named UK Quoted Company Entrepreneur, UK Life Science Public Company, UK Iconic Male Entrepreneur, European Life Science Business Leader and Scrip Biotech and Pharma Executive of Year as well as one of the 100 game-changing disruptive UK entrepreneurs.
Darrin supports education, entrepreneurship and mentoring programs in the UK, via the Professor Christopher R Lowe Carpe Diem Enterprise Fund, and has backed over 40 start-up life science, technology and social enterprises.
Darrin is an Enterprise Fellow at the Department of Chemical Engineering and Biotechnology, University of Cambridge, Honorary Fellow of the Cambridge Judge Business School and Honorary Visiting Fellow at the School of Environmental and Life Science at the University of Salford.
He holds a BSc in Chemistry and a DSc (Honoris Causa) from the University of Salford and a PhD in Biotechnology from the University of Cambridge.
In 2016 Darrin was conferred with a lifetime-held Queens Award for Enterprise Promotion and in 2018 was appointed Officer of the Order of the British Empire by Queen Elizabeth II for his services to business and enterprise in the healthcare sector.